ICT also modulates the tumor immune microenvironment by directly binding to MyD88 or IKKα to inhibit the TLR-MyD88-IKK-NF-κB inflammatory pathway, reducing the production of inflammatory cytokines such as TNF-α and IL-6 (78). Here, NFKB1 is linked to neoplasm.